CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Enhanced Disease-Free Survival in ALK-Positive NSCLC with Alectinib
In a pivotal phase 3 trial, adjuvant alectinib demonstrated significant improvement in disease-free survival rates compared to traditional platinum-based chemotherapy in patients with resected ALK-positive non-small-cell lung cancer (NSCLC). This landmark study underscores the potential of targeted therapies to redefine post-surgical outcomes, offering a promising alternative to conventional chemotherapy regimens.
Key Points:
- The study involved a global, phase 3, open-label, randomized trial focusing on patients with completely resected, ALK-positive NSCLC at stages IB (tumors ≥4 cm), II, or IIIA.
- Patients were randomly assigned to receive either oral alectinib (600 mg twice daily for 24 months) or traditional intravenous platinum-based chemotherapy administered over four 21-day cycles.
- The primary endpoint of the study was disease-free survival, with a secondary focus on central nervous system (CNS) disease–free survival, overall survival, and safety profiles.
- After two years, the alectinib group showed a disease-free survival rate of 93.8% in patients with stage II or IIIA disease, significantly higher than the 63.0% observed in the chemotherapy group (hazard ratio for disease recurrence or death, 0.24; 95% CI, 0.13 to 0.45; P<0.001).
- In the intention-to-treat population, the rates were similarly high with alectinib at 93.6% compared to 63.7% for chemotherapy (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001).
- Alectinib also offered a clinically meaningful advantage in CNS disease-free survival with a hazard ratio of 0.22 (95% CI, 0.08 to 0.58) for CNS disease recurrence or death.
- Overall survival data were still immature at the time of reporting, with further analysis required.
- Safety profiles for alectinib did not reveal any unexpected adverse effects, suggesting good tolerability and manageable safety in comparison to traditional chemotherapy.
“Among patients with resected ALK-positive NSCLC, adjuvant alectinib not only significantly improved disease-free survival but also enhanced CNS disease-free outcomes, marking a substantial advancement in the management of this cancer subtype.”
More on Lung Cancer
